Alector (ALEC)

• Market cap: $255M
• 1 day: -7.14%
• 5 days: 11.96%
• 1 month: 32.95%
• 3 months: 85.71%
• 6 months: 32.20%
• Year to date: 23.81%
• 1 year: -56.26%
• 5 years: -82.35%
• 10 years: -87.00%
• Sector: Healthcare
• Industry: Biotechnology

About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Employees: 163

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,105% more call options, than puts

Call options by funds: $229K | Put options by funds: $19K

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

10% more capital invested

Capital invested by funds: $89.8M [Q1] → $98.4M (+$8.61M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

2.99% less ownership

Funds ownership: 73.28% [Q1] → 70.29% (-2.99%) [Q2]

6% less funds holding

Funds holding: 142 [Q1] → 133 (-9) [Q2]

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3.50 50% upside
• Avg. target: $3.50 50% upside
• High target: $3.50 50% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Mizuho Graig Suvannavejh

50% upside $3.50

Outperform Upgraded

28 Jul 2025